Epoprostenol for Patients on ECMO

(PACE Trial)

This trial tests a medication called epoprostenol (Veletri) to determine if it can safely prevent blood clots in children on ECMO. ECMO supports the heart and lungs when they are not functioning well. The trial aims to identify the safest dose of epoprostenol and assess its impact on blood clotting in children who are stable on ECMO. It suits children on ECMO with stable blood pressure who are already receiving blood thinners. As a Phase 1, Phase 2 trial, it focuses on understanding how the treatment works in people and measuring its effectiveness in an initial, smaller group.

Research has shown that epoprostenol, also known as Veletri, is generally safe for patients. One study found no new safety issues, and most patients tolerated it well. This medication primarily treats high blood pressure in the lungs and has FDA approval for this use. However, it can affect blood clotting, which is crucial for people on ECMO (a machine that aids breathing and circulation) because the machine can cause blood clots. The current study aims to determine the safest dose for people on ECMO and closely monitors side effects such as changes in blood pressure, unexpected bleeding, and fluid in the lungs.¹²³⁴⁵

Epoprostenol (Veletri) is unique because it directly targets blood vessels to cause dilation, potentially improving blood flow in patients on ECMO (extracorporeal membrane oxygenation) support. Unlike standard treatments for ECMO patients, which often focus on mechanical support and anticoagulation, epoprostenol works by mimicking a natural compound in the body called prostacyclin. Researchers are excited about epoprostenol because it might enhance oxygen delivery and reduce complications associated with ECMO therapy more effectively than current options. This targeted approach could lead to better outcomes and faster recovery times for patients.

Research has shown that epoprostenol, a medication often used for high blood pressure in the lungs, can help prevent blood clots by reducing platelet activity. This is crucial for patients using ECMO, a machine that supports heart and lung function, where clotting can be problematic. Studies have found that epoprostenol can improve oxygen levels in the blood for patients with serious lung issues. In this trial, participants will receive different doses of epoprostenol based on their weight, potentially lowering the risk of clotting in ECMO situations due to its ability to reduce platelet activity.⁶⁷⁸⁹¹⁰